Smith, Samuel G. http://orcid.org/0000-0003-1983-4470
Sestak, Ivana
Morris, Michelle. A.
Harvie, Michelle
Howell, Anthony
Forbes, John
Cuzick, Jack
Clinical trials referenced in this document:
Documents that mention this clinical trial
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
https://doi.org/10.1007/s10549-021-06141-7
A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo – A substudy for IBIS I Breast Cancer Prevention Trial
https://doi.org/10.1016/j.ejca.2012.06.015
Documents that mention this clinical trial
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
https://doi.org/10.1007/s10549-021-06141-7
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
https://doi.org/10.1016/s0140-6736(13)62292-8
Funding for this research was provided by:
Cancer Research UK (C569/A5032, C569/A16891, C8162/A26893)
Astrazeneca
Sanofi
Yorkshire Cancer Research
NIHR Manchester Biomedical Research Centre
Prevent Breast Cancer
Article History
Received: 13 October 2020
Accepted: 8 February 2021
First Online: 3 March 2021
Declarations
:
: MM is inventor and shareholder at Dietary Assessment Limited. SS, IS, MH, AH, JF and JC declare no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of local ethics committees for each participating site (IBIS-I trial) and the UK North West Multicentre Research Ethics Committee (IBIS-II) and with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all individual participants included in the study.